Analysts Anticipate Gamida Cell Ltd (NASDAQ:GMDA) Will Post Earnings of -$0.37 Per Share

Brokerages predict that Gamida Cell Ltd (NASDAQ:GMDA) will report ($0.37) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Gamida Cell’s earnings. Gamida Cell posted earnings per share of ($14.23) in the same quarter last year, which would suggest a positive year over year growth rate of 97.4%. The business is expected to announce its next earnings report after the market closes on Wednesday, November 13th.

On average, analysts expect that Gamida Cell will report full-year earnings of ($1.16) per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of ($1.31) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Gamida Cell.

Several equities analysts have commented on the company. Oppenheimer set a $18.00 target price on Gamida Cell and gave the company a “buy” rating in a research report on Wednesday, August 7th. JMP Securities assumed coverage on Gamida Cell in a research report on Friday, September 20th. They set an “outperform” rating and a $16.00 price objective for the company. Zacks Investment Research downgraded Gamida Cell from a “buy” rating to a “hold” rating in a research report on Wednesday, October 9th. Finally, ValuEngine upgraded Gamida Cell from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $16.43.

Several institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada acquired a new stake in Gamida Cell during the second quarter worth approximately $71,000. Bank Hapoalim BM acquired a new stake in Gamida Cell during the second quarter worth approximately $195,000. EcoR1 Capital LLC acquired a new stake in Gamida Cell during the second quarter worth approximately $265,000. Noked Capital LTD acquired a new stake in Gamida Cell during the second quarter worth approximately $1,035,000. Finally, Rock Springs Capital Management LP acquired a new stake in Gamida Cell during the second quarter worth approximately $5,080,000. Institutional investors own 25.70% of the company’s stock.

Gamida Cell stock traded down $0.10 during trading hours on Wednesday, hitting $4.85. The stock had a trading volume of 304 shares, compared to its average volume of 24,554. The company has a quick ratio of 4.47, a current ratio of 4.47 and a debt-to-equity ratio of 0.23. The stock has a market cap of $117.96 million and a price-to-earnings ratio of -0.46. Gamida Cell has a one year low of $2.93 and a one year high of $15.41. The business’s 50 day simple moving average is $4.64 and its 200-day simple moving average is $5.27.

About Gamida Cell

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

See Also: What is the QQQ ETF?

Get a free copy of the Zacks research report on Gamida Cell (GMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.